PharmaTimesNews & Politicsnews

Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis

Tuesday, May 12, 2026John PinchingView original

Lead candidate ETD001 delivers significant lung function improvement

Read the full article on the original site.

Read Full Article